Therapeutical strategies in metastatic pheochromocytoma;Die therapeutischen Moglichkeiten bei metastasiertem Phaochromozytom

Zentralblatt fur Chirurgie

Volumn 122, Issue 6, 1997, Pages 494-497

  Vierhapper, H ^a   Raber, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

131 meta Iodobenzylguanidin; Adrenal gland; Chemotherapy; Malignant pheochromocytoma; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; STREPTOZOCIN; VINCRISTINE; (3 IODOBENZYL)GUANIDINE; ANTINEOPLASTIC AGENT; IODOBENZENE; RADIOACTIVE IODINE;

ARTICLE; CANCER SURVIVAL; HUMAN; METASTASIS; PHEOCHROMOCYTOMA; TREATMENT INDICATION; TUMOR LOCALIZATION; ADJUVANT CHEMOTHERAPY; ADRENAL TUMOR; MORTALITY; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; HUMANS; IODINE RADIOISOTOPES; IODOBENZENES; NEOPLASM METASTASIS; PHEOCHROMOCYTOMA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030801043     PISSN: 0044409X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Anonymous (1984) Iodobenzylguanidine for localization and treatment of pheochromocytoma. Lancet II: 905-907
2. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR (1988) Malignant pheochromocytoma: effective treatment with a combination of cyclo-phosphamide, vincristine, and dacarbazine. Ann Int Med 109: 267-273
3. Badet C (1990) Les phéochromocytomes malins. Etude de 14 observations. Revue de la litérature. Thèse Lyon: University of Lyon, Ed., Lyon
4. Brennan MF, Keiser HJ (1982) Persistent and recurrent pheochromocytoma: the role of surgery. World J Surg 6: 397-402
5. Chatal JF, Charbonnel B (1985) French MIBG Study Group. Comparison of iodobenzylguanidine imaging with computed tomography in locating pheochromocytoma. J Clin Endocrinol Metab 61: 769-772
6. De Asis D, Ali MK, Soto A, Samaan NA (1978) Acute cardiac toxicity of antineoplastic agents as the first manifestation of pheochromocytoma. Cancer 42: 2005-2008
7. Dow DC, Palmer MK, O'Sullivan JP, Kirkham JS (1982) Malignant phaeochromocytoma: report of a case and a critical review. Br J Surg 69: 338-340
8. Engelman K, Horwitz D, Jequier E, Sjoerdsma A (1968) Biochemical and pharmacologic effects of alpha-methyltyrosine in man. J Clin Invest 47: 577-594
9. Feldman, JM (1983) Treatment of metastatic pheochromocytoma with streptozocin. Arch Intern Med 143: 1799-1800
10. Hamilton BP, Cheikh IE, Rivera LE (1977) Attempted treatment of inoperable pheochromocytoma with streptozocin. Arch Intern Med 137: 762-765
11. Herrera LO, Hossein ZM, Rafal HS, Frelick RW, Ashley PF, Lopez GE (1980) Malignant pheochromocytoma (paraganglioma) of the organ of Zuckerkandl: a study of two cases. J Surg Oncol 14: 133-145
12. 131I]Iodobenzylguanidine in the treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 72: 455-461
13. Mornex R, Badet C, Peyrin L (1995) Malignant pheochromocytoma: A series of 14 cases observed between 1960 and 1990. J Endocrinol Invest 15: 643-649
14. Picco P, Garaventa A, Claudiani F, Gattorno M, De Bernardi B, Borrone C (1995) Primary hypothyroidism as a consequence of 131-I-Metabiodobenzylguanidine treatment for children with neuroblastoma. Cancer 76: 1662-1664
15. Proye C, Viix M, Goropoulos A, Kerlo P, Lecomte-Houcke M (1992) High incidence of malignant pheochromocytoma in a surgical unit. 26 cases out of 100 patients operated from 1971 to 1991. J Endocrinol Invest 15: 651-663
16. Pujol P, Bringer J, Faurous P, Jaffiol C (1995) Metastatic phaeochromocytoma with a long-term response after iodine -131 metaiodobenzylguanidine therapy. Eur J Nucl Med 22: 382-384
17. Remine WH (1974) Current management of pheochromocytoma. Ann Surg 179: 740-748
18. Schlumberger M, Gicquel C, Lumbroso J, Tenenbaum F, Comoy E, Bosq J, Fonseca E, Ghillani PP, Aubert B, Travagli JP, Gardet P, Permentier C (1992) Malignant pheochromocytoma: Clinical, biological, histological and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 15: 631-642
19. Schürmeyer TH, Engeroff B, von zur Mühlen A, Dralle H (1994) Symptomatik und endokrinologische Befunde bei katecholamin-sezernierenden Tumoren. Ergebnisse bei 106 konsekutiven Patienten. Dtsch Med Wochenschr 119: 1721-1727
20. Scott HW, Reynolds V, Green N, Page D, Oates JA, Robertson D (1982) Clinical experience with malignant pheochromocytomas. Surg Gynecol Obstet 154: 801-818
21. Senan S, Reed N, Connell J (1992) Palliation of malignant phaeochromocytoma with combination chemotherapy. Eur J Cancer 28A: 1006-1007
22. Shapiro B, Sisson JC (1988) Atlas of nuclear medicine. Philadelphia, JB Lippincott Co, p 72
23. Shapiro B, Fig LM (1989) Management of pheochromocytoma. Med Clin North Am 18: 443-481
24. Sisson JC, Shapiro B, Beierwaltes WH, Glownika JV, Najajo M, Mangner TJ, Carey JE, Swanson DP, Copp JE, Satterlee WG (1984) Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 24: 197-206
25. Taub MA, Osburnee RC, Georges LP, Sode J (1982) Malignant pheochroomocytoma. Severe clinical exacerbation and release of stored catecholamine during lymphoma chemotherapy. Cancer 50: 1739-1741
26. Timmis JB, Bown MJ, Allison DJ (1981) Therapeutic embolization of pheochromocytoma. Br J Radiol 54: 420-422
27. 131I-iodobenzylguanidine. J Nucl Med 21: 349-353
28. Young WF (1993) Pheochromocytoma: 1926-1993. TEM 4: 122-127